A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.

Andrés Felipe CardonaL RojasB WillsA Ruiz-PatiñoL AbrilF HakimE JiménezN UsecheS BermúdezJ A MejíaJ F RamónH CarranzaC VargasJ OteroP ArchilaJ RodríguezJ RodríguezJ BehaineD GonzálezJ JacoboH CifuentesO FeoP PenagosD PinedaL RicaurteL E PinoC VargasJ C MarquezM I MantillaL D OrtizC BalañaR RosellZ L Zatarain-BarrónO Arrieta

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)

BCNU/Bev is a safe and tolerable treatment for rGBM. Patients with MGMT+/IDH+ derive the greatest benefit from the treatment combination in the second-line setting. Nonetheless, high YKL40 expression discourages the use of antiangiogenic therapy.

Keyphrases

poor prognosis
stem cells
long non coding rna
smoking cessation
cell therapy
metastatic colorectal cancer
wild type